Market Overview

Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

Cidara Therapeutics Inc (NASDAQ: CDTX) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin.

The Analyst

Wedbush analyst Robert Driscoll upgraded Cidara from Neutral to Outperform and upped the price target from $2 to $4.

The Thesis

Cidara's partnership with Mundipharma is a significant positive, given the $30-million upfront payment, $9-million equity investment and near-term payments of $42 million, Driscoll said in a Tuesday upgrade note. (See his track record here.) 

In return, Mundipharma receives global commercial rights to rezafungin excluding the U.S. and Japan, the analyst said. 

Wedbush sees the total deal value to be in excess of $534 million.

The equity investment will be enacted by way of a private placement of 4.78 million new shares issued at $1.884 each, a 20% premium to the 10-day volume weighted average price, he said. 

"Additionally, we see substantial synergies between both companies given Mundipharma already has a significant global commercial reach with annual sales over €2B in a variety of therapeutic areas including diabetes, respiratory, oncology, pain and biosimilars," Driscoll said. 

The firm recommends buying Cidara shares given the removal of the financing overhang as well as an improving reimbursement environment for antibacterials and antifungals.

Specifically, Wedbush encourages long-term investors to buy into the shares ahead of the mid-2020 Phase 3 ReSTORE data readout.

The Price Action

Following the roughly 40% rally on Tuesday, Cidara shares were giving back some of the gains, trading down 11.91% at $2.07 at the time of publication Wednesday. 

Related Links:

The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Cidara Rallies On Development Deal For Lead Antifungal Medication

Latest Ratings for CDTX

Aug 2020CitigroupMaintainsBuy
Mar 2020NeedhamMaintainsBuy
Dec 2019WBB SecuritiesUpgradesSpeculative BuyBuy

View More Analyst Ratings for CDTX
View the Latest Analyst Ratings


Related Articles (CDTX)

View Comments and Join the Discussion!

Posted-In: Robert Driscoll WedbushAnalyst Color Biotech Upgrades Price Target Analyst Ratings General

Latest Ratings

INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at